Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Accumulated Expenses (2016 - 2025)

Fennec Pharmaceuticals filings provide 16 years of Accumulated Expenses readings, the most recent being $5.6 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 343.35% to $5.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.6 million, a 343.35% increase, with the full-year FY2025 number at $5.6 million, up 343.35% from a year prior.
  • Accumulated Expenses hit $5.6 million in Q4 2025 for Fennec Pharmaceuticals, up from $1.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $5.6 million in Q4 2025 to a low of $171000.0 in Q2 2021.
  • Median Accumulated Expenses over the past 5 years was $1.0 million (2023), compared with a mean of $1.3 million.
  • Biggest five-year swings in Accumulated Expenses: plummeted 70.35% in 2022 and later surged 368.85% in 2023.
  • Fennec Pharmaceuticals' Accumulated Expenses stood at $877000.0 in 2021, then plummeted by 70.35% to $260000.0 in 2022, then surged by 368.85% to $1.2 million in 2023, then grew by 4.27% to $1.3 million in 2024, then soared by 343.35% to $5.6 million in 2025.
  • The last three reported values for Accumulated Expenses were $5.6 million (Q4 2025), $1.3 million (Q3 2025), and $2.2 million (Q2 2025) per Business Quant data.